MedPath

Effect of Bivalirudin on Aortic Valve Intervention Outcomes.

Conditions
- patients undergoing TAVR via transfemoral access - aortic valve replacement- aortaklepvervanging
Registration Number
NL-OMON27624
Lead Sponsor
The Medicines Company8 Sylvan WayParsippany, NJ07054
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
620
Inclusion Criteria

1. ≥ 18 years of age;

2. High risk (Euroscore ≥18, or considered inoperable) for surgical aortic valve replacement;

Exclusion Criteria

1. Contraindication to bivalirudin or UFH;

2. Refusal to receive blood transfusion;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath